CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Apr 12, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of
www.p2dinc.com